Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

Metabolic screening in children receiving antipsychotic drug treatment.

Morrato EH, Nicol GE, Maahs D, Druss BG, Hartung DM, Valuck RJ, Campagna E, Newcomer JW.

Arch Pediatr Adolesc Med. 2010 Apr;164(4):344-51. doi: 10.1001/archpediatrics.2010.48. Erratum in: Arch Pediatr Adolesc Med. 2010 Jun;164(6):584.

PMID:
20368487
2.

Research in people with psychosis risk syndrome: a review of the current evidence and future directions.

Correll CU, Hauser M, Auther AM, Cornblatt BA.

J Child Psychol Psychiatry. 2010 Apr;51(4):390-431. doi: 10.1111/j.1469-7610.2010.02235.x. Epub 2010 Feb 26. Review.

3.

Report from the working group conference on multisite trial design for cognitive remediation in schizophrenia.

Keefe RS, Vinogradov S, Medalia A, Silverstein SM, Bell MD, Dickinson D, Ventura J, Marder SR, Stroup TS.

Schizophr Bull. 2011 Sep;37(5):1057-65. doi: 10.1093/schbul/sbq010. Epub 2010 Mar 1.

4.

Implementation of the thinking skills for work program in a psychosocial clubhouse.

McGurk SR, Schiano D, Mueser KT, Wolfe R.

Psychiatr Rehabil J. 2010 Winter;33(3):190-9.

PMID:
20061255
5.

Metabolic testing rates in 3 state Medicaid programs after FDA warnings and ADA/APA recommendations for second-generation antipsychotic drugs.

Morrato EH, Druss B, Hartung DM, Valuck RJ, Allen R, Campagna E, Newcomer JW.

Arch Gen Psychiatry. 2010 Jan;67(1):17-24. doi: 10.1001/archgenpsychiatry.2009.179.

PMID:
20048219
6.

The 2009 schizophrenia PORT psychosocial treatment recommendations and summary statements.

Dixon LB, Dickerson F, Bellack AS, Bennett M, Dickinson D, Goldberg RW, Lehman A, Tenhula WN, Calmes C, Pasillas RM, Peer J, Kreyenbuhl J; Schizophrenia Patient Outcomes Research Team (PORT).

Schizophr Bull. 2010 Jan;36(1):48-70. doi: 10.1093/schbul/sbp115. Epub 2009 Dec 2. Review.

7.

Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia.

Kinon BJ, Chen L, Ascher-Svanum H, Stauffer VL, Kollack-Walker S, Zhou W, Kapur S, Kane JM.

Neuropsychopharmacology. 2010 Jan;35(2):581-90. doi: 10.1038/npp.2009.164.

8.

Second-generation antipsychotic long-acting injections: systematic review.

Fleischhacker WW.

Br J Psychiatry Suppl. 2009 Nov;52:S29-36. doi: 10.1192/bjp.195.52.s29. Review.

PMID:
19880914
9.
10.

Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents.

Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK.

JAMA. 2009 Oct 28;302(16):1765-73. doi: 10.1001/jama.2009.1549. Erratum in: JAMA. 2009 Dec 2;302(21):2322.

11.

Clinical trials design lessons from the CATIE study.

Kraemer HC, Glick ID, Klein DF.

Am J Psychiatry. 2009 Nov;166(11):1222-8. doi: 10.1176/appi.ajp.2009.08121809. Epub 2009 Oct 1. Review.

PMID:
19797435
12.

The cognitive cost of anticholinergic burden: decreased response to cognitive training in schizophrenia.

Vinogradov S, Fisher M, Warm H, Holland C, Kirshner MA, Pollock BG.

Am J Psychiatry. 2009 Sep;166(9):1055-62. doi: 10.1176/appi.ajp.2009.09010017. Epub 2009 Jul 1.

13.

The value, qualification, and regulatory use of surrogate end points in drug development.

Lathia CD, Amakye D, Dai W, Girman C, Madani S, Mayne J, MacCarthy P, Pertel P, Seman L, Stoch A, Tarantino P, Webster C, Williams S, Wagner JA.

Clin Pharmacol Ther. 2009 Jul;86(1):32-43. doi: 10.1038/clpt.2009.69. Epub 2009 May 27. Review.

PMID:
19474783
14.

Proceedings and data from The Schizophrenia Summit: a critical appraisal to improve the management of Schizophrenia.

Nasrallah HA, Keshavan MS, Benes FM, Braff DL, Green AI, Gur RE, Kane JM, Perkins DO, Weiden PJ, Weinberger DR, Correll CU.

J Clin Psychiatry. 2009;70 Suppl 1:4-46.

15.

Are the cardiometabolic complications of schizophrenia still neglected? Barriers to care.

Lambert TJ, Newcomer JW.

Med J Aust. 2009 Feb 16;190(4 Suppl):S39-42. Review.

PMID:
19220173
16.

Clozapine versus typical neuroleptic medication for schizophrenia.

Essali A, Al-Haj Haasan N, Li C, Rathbone J.

Cochrane Database Syst Rev. 2009 Jan 21;(1):CD000059. doi: 10.1002/14651858.CD000059.pub2. Review.

PMID:
19160174
17.

Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis.

Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM.

Lancet. 2009 Jan 3;373(9657):31-41. doi: 10.1016/S0140-6736(08)61764-X. Epub 2008 Dec 6.

PMID:
19058842
18.

Muscarinic agonists for the treatment of cognition in schizophrenia.

Sellin AK, Shad M, Tamminga C.

CNS Spectr. 2008 Nov;13(11):985-96. Review.

PMID:
19037177
19.

A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia.

Leucht S, Komossa K, Rummel-Kluge C, Corves C, Hunger H, Schmid F, Asenjo Lobos C, Schwarz S, Davis JM.

Am J Psychiatry. 2009 Feb;166(2):152-63. doi: 10.1176/appi.ajp.2008.08030368. Epub 2008 Nov 17.

PMID:
19015230
20.

A roadmap to disentangle the molecular etiology of schizophrenia.

Falkai P, Mike O, Inez MG, Paul H, Andras BG, Sophia F; MEOS Consortium.

Eur Psychiatry. 2008 Jun;23(4):224-32. doi: 10.1016/j.eurpsy.2008.02.006. Epub 2008 Jun 25. Review.

PMID:
18583106

Supplemental Content

Support Center